Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Methodon Nov 25, 2020 7:48am
133 Views
Post# 31968004

RE:RE:RE:RE:YouTube Interview

RE:RE:RE:RE:YouTube Interview

The multiple is on the cash flow. Just adjust the share count for the dilution and don't forget to add the interest back to the cash flow. 

As for the "pumping" accusation. Presumably any of us long the stock, think it's cheap and appreciate Eden for shining a light on the story. I'm not sure why you want to besmirch the man's character for repeating what the CEO said on YouTube a month earlier. 

 


mjh9413 wrote: Few of points to add.
Doubt if one can apply a 10x multiple to this company.
Presume the 50c+ options (3,8MM) have probably expired 
The Conv Deb holders are the ongoing winners when it comes to an stakeholders benefitting..They have been in from about 2008 on and the current 23c conv price was down from original 65c and 90c (and int rates increased) because a credit facility with TD needed the deb holders consent to amend their collateral rights. I believe some deb holders also got additional 23c warrants at the time. It is one of the features I don;t like about their financials for despite the debs being long-dated they really are dilutive and a cash burden. I have not found any reference to the original deals on SEDAR and all the company docs refer simply to holders being  'shareholders of the company' no names.
As I said, mine is a bet based on what they define as possible revs from QAPs. As to the guy on BNN, well he would pump the stock:I see the firm has probably about $1MM invested.



 

<< Previous
Bullboard Posts
Next >>